New hope for tough lymphoma cases: experimental combo shows promise
NCT ID NCT03458260
Summary
This study tested whether adding the experimental drug pixantrone to three existing lymphoma medications could help control aggressive non-Hodgkin lymphoma that has returned or stopped responding to previous treatments. The trial involved 74 adults whose cancer had relapsed or was resistant to standard therapies. Researchers measured how well the combination shrank tumors and monitored side effects to see if it could be a viable option for these difficult-to-treat cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Sint Jan
Bruges, Belgium
-
CH d'Avignon
Avignon, France
-
CH de Cornouaille
Quimper, France
-
CHRU de Lille
Lille, France
-
CHU Jean Minjoz
Besançon, France
-
CHU Lyon Sud
Lyon, France
-
CHU de Poitiers
Poitiers, France
-
CHU de Rouen
Rouen, France
-
CHU de Strasbourg
Strasbourg, France
-
CHU de Tours
Tours, France
-
CHU de la Conception
Marseille, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier William Morey
Chalon-sur-Saône, France
-
Centre Hospitalier de Jolimont
Haine-Saint-Paul, Belgium
-
Centre Hospitalier de la Côte Basque
Bayonne, France
-
Centre Lacassagne
Nice, France
-
Clinique Victor Hugo
Le Mans, France
-
Hopital La Pitié Salpétriere
Paris, France
-
Hôpital Haut-Lévèque
Bordeaux, France
-
Hôpital Robert Debré
Reims, France
-
Hôpital St louis
Paris, France
-
Institut Jules Bordet - Centre des tumeurs de l'ULB
Brussels, Belgium
Conditions
Explore the condition pages connected to this study.